Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 15,354.40 121.18 0.80%
S&P 500 1,667.47 17.00 1.03%
NASDAQ 3,498.96 33.72 0.97%
Ticker Volume Price Price Delta
STOXX 50 2,817.99 11.29 0.40%
FTSE 100 6,723.06 35.26 0.53%
DAX 8,398.00 28.13 0.34%
Ticker Volume Price Price Delta
NIKKEI 15,138.12 100.88 0.67%
TOPIX 1,253.24 8.01 0.64%
HANG SENG 23,082.68 38.44 0.17%

Apricus Biosciences Announces 2012 Year End Financial Results Conference Call



Apricus Biosciences Announces 2012 Year End Financial Results Conference Call

Conference Call/Webcast to be Held Monday, March 18, 2013 at 1:00 p.m. ET

SAN DIEGO, March 14, 2013 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc.
("Apricus Bio" or the "Company") (Nasdaq:APRI) (www.apricusbio.com) announced
today that it will hold a conference call to discuss its year end 2012
financial results and recent corporate highlights on Monday, March 18, 2013 at
1:00 p.m. ET. The Company expects to file its Form 10-K for the year ended
December 31, 2012 on Monday, March 18, 2013.

The call can be accessed in the U.S. by dialing 877-407-8031 and outside of
the U.S. by dialing 201-689-8031 and asking the conference operator for the
Apricus Bio Conference Call. The teleconference replay will be available for
one week by dialing in the U.S. 877-660-6853 and outside of the U.S. by
dialing 201-612-7415. Replay passcode 410469 is required for playback. The
conference call will also be webcast live at
http://www.investorcalendar.com/IC/CEPage.asp?ID=170645. The webcast replay
will be available for three months.

About Apricus Biosciences, Inc.

Apricus Biosciences, Inc. (Nasdaq:APRI) is a pharmaceutical company that
develops and markets innovative treatments that help large patient populations
across numerous, large-market therapeutic classes including male and female
sexual health. The Company has one approved product, Vitaros®, for the
treatment of erectile dysfunction, which will be marketed in Canada by Abbott
Laboratories, and Femprox®, a product candidate, for the treatment of female
sexual arousal disorder, which successfully completed a nearly 400-subject
Phase III study in China.

For further information on Apricus Bio, visit http://www.apricusbio.com. You
can also receive information at http://twitter.com/apricusbio.

CONTACT: Apricus Bio Investor Relations:
        
         David Pitts or Lourdes Catala
         Argot Partners
         212-600-1902
         david@argotpartners.com
         lourdes@argotpartners.com

Apricus logo
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement